Notice of Proposed Sale · 144
Viking Therapeutics, Inc.
VKTXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- VIKING THERAPEUTICS, INC.
- Issuer CIK
- 0001607678
- SEC file number
- 001-37355
- Phone
- (858) 704-4660
- Person for whose account securities are to be sold
- BRIAN LIAN
- Relationships to issuer
- Officer
- Street
- 9920 Pacific Heights Blvd, Suite 350
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 148,517 | 4,947,888.41 | 116,105,643 | 07/29/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/28/2026 | Performance Stock Units | Issuer | 148,517 | N | 07/29/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
Sale is to cover taxes for vesting.
Notice signature
- Notice date
- 07/29/2026
- Signed
- /s/ Brian Lian
Company context
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management. Viking is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).
Current securities
Historical securities (1)
Recent company filings
- SCHEDULE 13G/A - filed by FMR LLC regarding Viking Therapeutics, Inc.Nov 5, 2026
- 10-Q filingOct 29, 2026
- Results of Operations and Financial ConditionOct 28, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementSep 28, 2026
- 424B5 filingSep 25, 2026